Gallium (68Ga)

Gallium (68Ga) is a radioactive isotope being extensively studied in clinical trials for its potential to revolutionize cancer diagnosis and treatment. This article explores various ongoing studies utilizing Gallium (68Ga) in positron emission tomography (PET) imaging for different types of cancers and other medical conditions. The research aims to improve diagnostic accuracy, assess treatment responses, and potentially guide personalized therapies.

Table of Contents

Introduction

Gallium (68Ga) is an innovative diagnostic tool that is being studied for its potential to improve the detection and assessment of various medical conditions. This article will provide an overview of Gallium (68Ga), its uses, and what patients can expect when undergoing imaging procedures using this substance.

What is Gallium (68Ga)?

Gallium (68Ga) is a radioactive isotope of gallium that is used in medical imaging. It is typically combined with other substances to create specialized imaging agents. These agents are designed to target specific tissues or processes in the body, allowing doctors to visualize and assess various medical conditions[1].

How Does It Work?

Gallium (68Ga) works by emitting positrons, which are detected by a special camera in a PET (Positron Emission Tomography) scanner. When combined with specific targeting molecules, Gallium (68Ga) can be directed to bind to certain types of cells or tissues in the body. This allows doctors to create detailed images of these areas and detect abnormalities that might not be visible with other imaging techniques[2].

Medical Conditions Diagnosed Using Gallium (68Ga)

Research is ongoing to explore the potential of Gallium (68Ga) in diagnosing and assessing various medical conditions. Some of the areas being studied include:

  • Cancer: Gallium (68Ga) is being investigated for its ability to detect and stage different types of cancer, including:
    • Gastro-esophageal cancer
    • Breast cancer
    • Prostate cancer
    • Multiple myeloma
    • Rectal cancer
  • Crohn’s Disease: Researchers are studying the use of Gallium (68Ga) to assess the healing of perianal fistulas in patients with Crohn’s disease[3].
  • Primary Aldosteronism: Gallium (68Ga) imaging is being evaluated for its potential to identify unilateral adrenal secretion of aldosterone in patients with this condition[4].

Benefits of Gallium (68Ga) Imaging

Gallium (68Ga) imaging offers several potential benefits:

  • Improved detection: It may be more sensitive in detecting certain types of cancer or other abnormalities compared to conventional imaging techniques.
  • Better staging: For cancer patients, it could provide more accurate information about the extent of the disease, helping doctors plan the most appropriate treatment.
  • Non-invasive: The imaging procedure is non-invasive, requiring only an injection of the imaging agent.
  • Personalized medicine: By providing detailed information about a patient’s condition, it could help doctors tailor treatments more effectively[5].

The Imaging Procedure

If you are scheduled for a Gallium (68Ga) imaging procedure, here’s what you can expect:

  1. You will receive an injection of the Gallium (68Ga) imaging agent through an intravenous (IV) line.
  2. There will be a waiting period to allow the imaging agent to circulate through your body and accumulate in the target tissues. This can take anywhere from a few minutes to a couple of hours, depending on the specific procedure.
  3. You will then lie on a table that moves through a PET scanner. The scanner detects the radiation emitted by the Gallium (68Ga) and creates detailed images of your body.
  4. The scanning process usually takes about 30-60 minutes.
  5. After the scan, you can typically resume your normal activities, but you may be advised to drink plenty of water to help flush the radioactive material from your system[6].

Safety and Side Effects

Gallium (68Ga) imaging is generally considered safe. The amount of radiation exposure is relatively low and the body eliminates the radioactive material quickly. However, as with any medical procedure, there are some considerations:

  • Pregnant women should not undergo this procedure due to potential risks to the fetus.
  • Breastfeeding women may need to temporarily stop breastfeeding after the procedure.
  • Some people may experience mild side effects such as pain at the injection site, nausea, or headache, but these are typically rare and short-lived[7].

Conclusion

Gallium (68Ga) imaging is an exciting area of medical research that holds promise for improving the diagnosis and management of various conditions, particularly in oncology. As research continues, it may become an increasingly important tool in personalized medicine, helping doctors to provide more accurate diagnoses and tailored treatments. If you’re scheduled for a Gallium (68Ga) imaging procedure, don’t hesitate to discuss any questions or concerns with your healthcare provider.

Cancer Type/Condition Gallium (68Ga) Compound Study Objective
Gastro-esophageal and HER2-low Breast Cancer [68Ga]Ga-ABY-025 Evaluate HER2 status in tumors and metastases
Marginal Zone Lymphoma [68Ga]Ga-PentixaFor Assess diagnostic performance for lymphoma staging
Prostate Cancer [68Ga]Ga-PSMA-11 Evaluate HER2 status and treatment response
Multiple Myeloma [68Ga]Ga-PentixaFor Improve risk and disease assessment
Perianal Crohn’s Fistulas [68Ga]Ga-FAPI-46 Visualize fibroblast activation during fistula healing
Primary Aldosteronism [68Ga]Ga-PentixaFor Identify unilateral adrenal aldosterone secretion
Early Rectal Cancer [68Ga]Ga-FAPI-46 Detect lymph node metastasis

Ongoing Clinical Trials on Gallium (68Ga)

  • Study of [68Ga]Ga-PentixaFor PET-CT Imaging in Patients with Metastatic Triple-Negative Breast Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France
  • Study Comparing [68Ga]Ga-PentixaFor PET/CT and AVS for Diagnosing Primary Aldosteronism in Patients with Hypertension

    Recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands
  • Study on the Safety and Effectiveness of [90Y]Y-PentixaTher in Patients with Recurrent or Resistant CNS Lymphoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Germany
  • Study on [68Ga]Ga-PentixaFor PET Imaging for Better Risk and Disease Assessment in Patients with Multiple Myeloma

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium The Netherlands
  • Study on the Use of 68Ga-EVG321 for Diagnosing Small Cell Lung Cancer in Patients

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany Italy
  • A Study Testing the Accuracy of 68Ga-Pentixafor PET/CT Imaging in Patients with Cardiac Sarcoidosis

    Not yet recruiting

    2 1 1
    Investigated drugs:
    The Netherlands
  • Comparing Lung Perfusion PET/CT-Guided Versus Standard Planning for Stereotactic Body Radiotherapy in Patients with Primary or Secondary Lung Tumors

    Not yet recruiting

    3 1 1
    France
  • Study of gallium-68 FAPI imaging to assess blood vessel changes in patients with pulmonary arterial hypertension receiving sotatercept

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    France
  • Study of [90Y]Y-PentixaTher and [68Ga]Ga-PentixaFor in patients with advanced Non-Hodgkin lymphomas: Evaluating radiopeptide-based imaging and therapy

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Germany
  • Study on [68Ga]Ga-PentixaFor PET Imaging for Identifying Unilateral Adrenal Aldosterone Secretion in Patients with Primary Aldosteronism

    Not recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Positron Emission Tomography (PET): A medical imaging technique that uses small amounts of radioactive materials called radiotracers to visualize and measure activity in the body's organs and tissues.
  • Gallium (68Ga): A radioactive isotope of gallium used in PET imaging, often attached to specific molecules to target and visualize cancer cells or other tissues of interest.
  • HER2: Human Epidermal growth factor Receptor 2, a protein that promotes the growth of cancer cells. Some breast cancers have higher levels of HER2 and are called HER2-positive.
  • Standardized Uptake Value (SUV): A measure used in PET imaging to quantify the concentration of radiotracer in a specific area of the body, helping to assess the intensity of cellular activity.
  • Tumor-to-Background Ratio (TBR): A measurement comparing the uptake of a radiotracer in a tumor to the uptake in surrounding normal tissue, used to evaluate the visibility of tumors in imaging.
  • Adrenal Vein Sampling (AVS): A procedure to determine if excess aldosterone production is coming from one or both adrenal glands, used in diagnosing primary aldosteronism.
  • CXCR4: A protein receptor found on the surface of some cells, including certain cancer cells, which can be targeted by specific radiotracers for imaging.
  • Fibroblast Activation Protein (FAP): A protein expressed in cancer-associated fibroblasts, which can be targeted by certain radiotracers to visualize tumors and their microenvironment.
  • Total Mesorectal Excision (TME): A surgical technique for removing rectal cancer along with surrounding fatty tissue and lymph nodes.
  • Prostate-Specific Membrane Antigen (PSMA): A protein found on the surface of prostate cells, often overexpressed in prostate cancer, which can be targeted for imaging and potential treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-gallium-68ga-tezatabep-matraxetan-pet-for-evaluating-her2-status-in-patients-with-gastro-esophageal-and-her2-low-breast-cancer/
  2. http://clinicaltrials.eu/trial/study-on-68gaga-pentixafor-and-18ffdg-pet-ct-imaging-for-staging-marginal-zone-lymphoma-in-patients-with-confirmed-diagnosis/
  3. http://clinicaltrials.eu/trial/study-on-gallium-68ga-chloride-for-early-healing-of-perianal-crohns-disease-fistulas-in-patients/
  4. http://clinicaltrials.eu/trial/study-on-68gaga-pentixafor-pet-imaging-for-identifying-unilateral-adrenal-aldosterone-secretion-in-patients-with-primary-aldosteronism/
  5. http://clinicaltrials.eu/trial/study-comparing-darolutamide-and-androgen-deprivation-therapy-to-placebo-and-androgen-deprivation-therapy-in-men-with-high-risk-prostate-cancer-recurrence/
  6. http://clinicaltrials.eu/trial/study-on-68gaga-pentixafor-pet-imaging-for-better-risk-and-disease-assessment-in-patients-with-multiple-myeloma/
  7. http://clinicaltrials.eu/trial/study-on-gallium-68ga-chloride-pet-ct-for-detecting-lymph-node-metastasis-in-patients-with-early-rectal-cancer/